ABSTRACT
A total of 40 patients with endoscopically proved reflux esophagitis were treated in a randomised study. Treatment was given for six weeks and consisted of daily doses of either 1 gm sucralfate four times a day or one, 150 mg ranitidine tablet twice daily. Twenty patients received each drug. Clinical evaluation was done weekly and endoscopic evaluation after six weeks. Forty percent patients on ranitidine and 50% patients on sucralfate became asymptomatic at six weeks. Fifty percent patients on ranitidine and 60% patients on sucralfate were endoscopically healed. The results did not show any difference in the effect of ranitidine and sucralfate treatment (p > 0.05). Overall tolerance and compliance in the two forms of treatment was good. Though ranitidine has a more convenient dose schedule and is more cost effective, sucralfate needs further clinical trials.
Subject(s)
Adult , Aged , Esophagitis, Peptic/drug therapy , Female , Humans , Male , Middle Aged , Patient Compliance , Ranitidine/therapeutic use , Sucralfate/therapeutic useABSTRACT
Forty patients with endoscopically proved reflux oesophagitis were treated in a randomised study. Treatment was given for six weeks and consisted of either 1 g sucralfate four times a day or 150 mg ranitidine tablet twice daily. Twenty patients received each drug. Clinical evaluation was done weekly and endoscopic evaluation after six weeks. Eight patients on ranitidine and ten patients on sucralfate became asymptomatic at six weeks. Ten patients on ranitidine and twelve patients on sucralfate were endoscopically healed. There was no difference in the effect of ranitidine and sucralfate treatment (p greater than 0.05). Overall tolerance and compliance with the two forms of treatment were good. Though ranitidine has a more convenient dose schedule and is more cost-effective, sucralfate needs further clinical evaluation.
Subject(s)
Adult , Esophagitis, Peptic/drug therapy , Female , Humans , Male , Ranitidine/therapeutic use , Sucralfate/therapeutic useABSTRACT
Twenty patients with endoscopically proved reflux esophagitis were studied. Each patient was given 1 gm sucralfate 4 times a day for 6 weeks. Clinical and endoscopic assessment of the effects of sucralfate on reflux esophagitis was done. 50% patients became asymptomatic and 60% healed endoscopically. The drug was well tolerated. We conclude that sucralfate is an effective and well tolerated drug for treatment of reflux esophagitis.